Introduction: Recent literature proposes that amyloid-b and phosphorylated tau (p-tau) synergism accelerates biomarker abnormalities in controls. Yet, it remains to be answered whether this synergism is the driving force behind Alzheimer disease (AD) dementia. Methods: We stratified 314 mild cognitive impairment individuals using [ 18 F]florbetapir positron emission tomography amyloid-b imaging and cerebrospinal fluid p-tau. Regression and voxelbased logistic regression models with interaction terms evaluated 2-year changes in cognition and clinical status as a function of baseline biomarkers. Results: We found that the synergism between [
Introduction
Alzheimer disease (AD) is characterized by the progressive accumulation of extracellular amyloid-b (Ab) plaques, intracellular inclusions of hyperphosphorylated tau in tangles, and neuronal degeneration [1] . The most widely accepted model of AD progression proposes a cascade of neuropathological events in which abnormal levels of Ab, neurofibrillary tangles, and neurodegeneration precede dementia [1] . The idea of pathophysiological progression was incorporated by the National Institute on Aging and the Alzheimer's Association 1 Data used in preparation of this article were obtained from the AD Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wpcontent/uploads/how_to_ap-ply/ADNI_Acknowledgement_List.pdf. *Corresp criterion for predementia phase of AD, which recognizes that the coexistence of abnormal Ab and neurodegeneration biomarkers better identify mild cognitive impairment (MCI) patients who will progress to dementia [2] . This notion has been supported by recent observations demonstrating that MCI Ab1 individuals with neurodegenerative changes, measured by brain hypometabolism or atrophy, have higher rates of neuropsychological decline as compared with MCI biomarker negative participants [3] [4] [5] . Yet, a key question that remains unanswered is whether the highest rate of progression to dementia in MCI Ab1 individuals with downstream cascade abnormalities is due to a synergistic effect between the coexistent brain pathologies or simply the sum of their deleterious effects. This question is particularly important in the context of the two hallmark proteinopathies underlying AD [6] . Although Ab and phosphorylated tau (p-tau) proteins well characterize AD pathophysiology, brain hypometabolism or atrophy may be found in several other brain disorders associated with neuronal loss [2, 7] . Given the emphasis of the current literature on the combination of Ab and neuronal degeneration biomarkers [3] [4] [5] 8] , the clinical fate of MCI patients with abnormal Ab plus p-tau proteins is scarcely known. The importance of characterizing the synergistic effect between Ab and p-tau on the development of dementia goes beyond the understanding of the mechanisms of disease progression. Determination of such synergism has immediate implications for the population enrichment of clinical trials testing anti-amyloid or anti-tau therapy. For example, if Ab and p-tau synergistically determine dementia, the enrichment of clinical trial populations with carriers of both pathologies would increase the rate of clinical progression without loss of therapeutic effectiveness. Conversely, if Ab and p-tau simply add their deleterious effects on cognitive decline, carriers of both pathologies would lead to a reduced therapeutic effectiveness of an intervention targeting only one of these proteinopathies, given the residual effect of the untreated protein on the clinical course of the disease.
Although several studies have shown that Ab and p-tau independently predict disease progression [9, 10] , a hypothetical framework proposes that both proteinopathies synergistically potentiate downstream neurodegeneration [11] . The presence of such a synergism would suggest that the effect of Ab and p-tau on the progression of AD taken together is greater than the sum of their separate effects at the same level. In fact, recent findings from our laboratory support this framework showing that the synergistic effect between brain Ab and p-tau rather than neurodegeneration drives AD-related metabolic decline in a cognitively normal population [12] . Similarly, in vivo studies conducted in controls have suggested that p-tau modulates the link between Ab and brain atrophy or behavioral changes [13] [14] [15] , whereas animal model literature has demonstrated a synergistic effect between Ab and p-tau peptides, leading to downstream synaptic and neuronal dysfunctions [16] .
Here, in a longitudinal analysis conducted in amnestic MCI individuals, we tested the hypothesis that the synergism between Ab aggregation and tau hyperphosphorylation determines progression from amnestic MCI to AD dementia.
Materials and methods

Database description and study participants
Data used in the preparation of this article were obtained from the Alzheimer's disease Neuroimaging Initiative (ADNI) database. ADNI was launched in 2003 as a publicprivate partnership, led by a principal investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF), and clinical assessment can be combined to measure the progression of MCI and early AD.
For the present study, we selected 314 ADNI-GO/2 participants meeting the criteria for single-domain or multidomain amnestic MCI, who underwent lumbar puncture and [ 18 F]florbetapir PET imaging at baseline as well as neuropsychological assessments at both baseline and at a 2-year follow-up. The eligibility criteria for selecting MCI were participants who had a Mini-Mental State Examination (MMSE) score equal to or greater than 24, a clinical dementia rating of 0.5, subjective and objective memory loss, and absence of other neuropsychiatric disorders [17] . (Further information about the inclusion/exclusion criteria may be found at www.adni-info.org [accessed September 2016].)
CSF analyses
The multiplex xMAP Luminex platform (Luminex Corp, Austin, TX, USA) was used to quantify p-tau at threonine 181 using INNO-BIA AlzBio3 immunoassay kit-based reagents (Innogenetics, Ghent, Belgium). All of the CSF p-tau data used in this study were obtained from the ADNI files "UPENNBIOMK5-8.csv." The data were statistically rescaled based on the baseline assay analysis that was used to define the CSF p-tau threshold [18] . We considered a subject positive for tau hyperphosphorylation if the CSF p-tau value was above the ADNI published threshold (.23 pg/ mL) [19, 20] . (Further details can be found at www. adni-info.org [accessed September 2016].)
MRI/PET methods
The schematic representation of the image analysis methods is presented in Fig. 1 
Biomarker-based stratification of participants
For analysis purposes, we divided the 314 MCI participants into four biomarker groups using the previously described [ 18 F]florbetapir and p-tau thresholds. At baseline, out of 314 individuals, 47 (15%) were biomarker negative (Ab2/p-tau2), 37 (12%) had only abnormal [ 18 F]florbetapir (Ab1/p-tau2), 62 (20%) had only abnormal p-tau (Ab2/ptau1), and 168 (53%) showed abnormal [ 18 F]florbetapir and p-tau (Ab1/p-tau1).
Statistical methods
The statistical analyses were performed using the R Statistical Software Package version 3.1.2 with RMINC library (http://www.r-project.org/; accessed September 2016). Neuropsychological test scores were analyzed using z-scores anchored in normative data obtained from the ADNI cognitively normal controls (n 5 162). Controls had a MMSE of 24 or greater, a CDR of 0, had no neuropsychiatric diagnosis including MCI and dementia, and performed the same protocols for data collection as the studied MCI population. All analyses involving neuropsychological measurements were repeated for each of the seven neuropsychological tests at baseline as well as for longitudinal changes between baseline and follow-up, where cognitive progression was measured using the difference between z-scores. 245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305   306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366 Analysis of covariance (ANCOVA) was performed to test for significant differences between groups (coded as a factor with four levels) on neuropsychological functions. P values were corrected for multiple comparisons using Bonferroni, and a significance level of .05 was used to interpret the results. Post hoc analysis provided significant differences between groups.
To evaluate the synergistic effect between Ab and p-tau on neuropsychological changes, ANCOVA models were fitted using both biomarkers as main effects as well as an interaction term between biomarkers. To evaluate if Ab and p-tau values predict cognitive changes across biomarker groups, a stratified linear regression analysis was performed in each of the four biomarker groups using change in test as the outcome and biomarker levels as the main covariate. Another model was fitted to evaluate if the effect of biomarker levels on cognitive changes differed significantly between the biomarker groups by adding in the model a main effect for biomarker groups, as well as an interaction term between biomarker groups and biomarker levels. Subsequently, to characterize the effects of abnormal Ab and p-tau status on the clinical progression to dementia, a logistic regression analysis was performed using progression as the outcome, biomarker status as the two main effects, and an interaction term between biomarkers.
Voxel-based logistic regression analysis
Furthermore, to identify the brain regions susceptible to the synergism between Ab and p-tau, a voxel-based logistic regression model was built to test the interactive and main effects between CSF p-tau status and [
18 F]florbetapir SUVR at every brain voxel on the likelihood of developing dementia [21] , assuming the probability of progression as b p; ðprogression51Þ.
The voxel-based statistical parametric maps were corrected for multiple testing. Statistical significance was defined using a Random Field Theory at a threshold of P , .001 [22] . We further adjusted the voxel-based model for the gray-matter density at every voxel to correct our results for gray-matter atrophy effects [21] . All Q3 analyses were adjusted for age, gender, years of formal education, APOE ε4 status, and baseline neuropsychological scores (only for models involving longitudinal changes), and varying intervals between cognitive assessments were also considered in the models.
Results
Demographics and key population characteristics are summarized in Table 1 . The biomarker groups did not differ in age, gender, or years of education. The proportion of APOE ε4 carriers was higher in Ab1/p-tau1 (63%) than in the other three groups (24%) (P , .001).
Synergistic effect between Ab and p-tau predicts the rate of cognitive decline in MCI individuals
ANCOVA models revealed that the Ab1/p-tau1 group had the worst baseline score and the highest rate of decline in most of the neuropsychological tests when compared with all other biomarker groups (Fig. 2) . Interestingly, the baseline and longitudinal cognitive performances of the Ab1/p-tau2 and Ab2/p-tau1 groups were similar to those of the biomarker negative group (Fig. 2) . Notably, our regression models confirmed that the synergistic interaction, rather than the sum of individual contributions of Ab1 and p-tau1 status, determined worse baseline performance or higher rate of impairment over time on the MMSE, ADASCog, LMI, LM30, and TMT-B for the Ab1/p-tau1 group (P , .05). Stratified regression analysis revealed that high CSF p-tau continuous values predicted worse scores in MMSE, ADAS-Cog, LMI, and LM30 only in the Ab1/ p-tau1 group (Table 2) . Interaction models between CSF p-tau values and the biomarker groups showed that the effects of CSF p-tau values in predicting declines in LMI and LM30 were significantly higher in Ab1/p-tau1 when compared with other biomarker groups (P , .01).
Ab and p-tau values
Synergistic effect between Ab and p-tau predicts progression from MCI to AD
Although Ab1 and p-tau1 status independently predicted dementia (P , .05), a significant interaction term with no significant main effects between Ab and p-tau status on progression to dementia revealed that Ab1/p-tau1 individuals showed a rate of progression greater than the sum of the independent contributions of Ab1 and p-tau1 (P , .05).
Furthermore, a multivariate logistic regression revealed that the presence of Ab1/p-tau1 was the strongest factor associated with developing dementia with a 14.1-fold (95% CI 5.7-38, P , .0001) increase in likelihood of progression. APOE ε4 status (OR 5 5.7, 95% CI 3.1-12, P , .0001) also predicted likely progression to dementia. Furthermore, [ 18 F]florbetapir SUVR values (OR 5 2.0, 95% CI 1.31-3.1, P 5 .001) and CSF p-tau values (OR 5 1.47, 95% CI 1.14-1.96, P 5 .004) predicted dementia exclusively in Ab1/p-tau1 group.
The overall progression rate to probable AD dementia of this study was 19% over 2 years. Among Ab2/p-tau2, Ab1/p-tau2, Ab2/p-tau1, and Ab1/p-tau1 participants, the progression rate was 4%, 3%, 3%, and 32%, respectively (Fig. 3) . Out of 59 participants who converted to dementia, 54 (92%) were Ab1/p-tau1 at baseline.
Synergistic effect between Ab and p-tau in temporoparietal regions predicts progression from MCI to AD
Voxel-based logistic regression analysis revealed that lateral and basal temporal and inferior parietal cortices are the brain regions where the synergistic effect between [ 18 F]florbetapir SUVR and CSF p-tau determined the increased likelihood of progression from amnestic MCI to AD dementia over a 2-year period (Fig. 4) .
Discussion
In this study, we found that amnestic MCI Ab1/ptau1 individuals had the highest rate of cognitive decline and progression to dementia, as compared to all other biomarker groups. Remarkably, our regression models confirmed that a synergistic rather than additive effect between Ab and p-tau determined greater cognitive decline and clinical progression in amnestic MCI Ab1/p-tau1. Furthermore, we found that only among amnestic MCI Ab1/p-tau1 individuals, did the baseline values of Ab and p-tau biomarkers predict cognitive and clinical impairments. Finally, a voxel-based analysis revealed that the temporal and inferior parietal cortices were the brain regions vulnerable to the synergism between Ab and p-tau peptides.
Overall, our results suggest the synergism between Ab and p-tau as an important element involved in the progression from amnestic MCI to AD dementia. This finding extends previous studies conducted in cognitively normal persons demonstrating that the synergism between Ab and p-tau determines functional and structural abnormalities [12] [13] [14] [15] . Interestingly, the temporal and inferior parietal cortices described here as the structural substrates in which the Ab and p-tau synergistic effect conferred an increased likelihood of clinical progression, are well known as vulnerable brain regions in patients who progressed from MCI to dementia [23] . Indeed, the synergistic effect between Ab and p-tau reported here is well supported by molecular studies describing synaptic and neuronal damages as consequences of the synergistic interactions between Ab and tau peptides [16, 24, 25] .
This study revealed that the link between Ab levels and progression to AD dementia depends on the p-tau status. This finding sheds light on the literature showing conflicting results reporting the association between Ab and cognition. Although the majority of studies describe a modest association in early disease stages [26] [27] [28] [29] [30] , others suggest that Ab 489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549   550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609 levels strongly predict cognitive decline in populations with a high probability to present p-tau abnormalities [9, 13] . Interestingly, Ab levels fail to predict time-to-progression to dementia in MCI Ab1 individuals with evidences of brain hypometabolism or atrophy [4] . One might claim that Ab levels represent an important predictor of forthcoming dementia, particularly in predementia persons with p-tau abnormalities [2] . Suspected non-Alzheimer disease pathophysiology (SNAP) has emerged as an important concept referring to patients showing a biomarker signature of neurodegeneration without Ab abnormalities [9] . As the concept of SNAP arises in our study as the group of MCI Ab2/ptau1 individuals [9] , we would like to comment on the clinical progression of this population. Previous studies have demonstrated that in SNAP MCI, characterized by the presence of neuronal degeneration evidenced by brain hypometabolism or atrophy, the rate of cognitive decline is higher than in MCI individuals who are biomarker negative and comparable to MCI carriers of Ab-plus neurodegeneration [4] [5] [6] . In contrast, we demonstrate here that SNAP MCI Ab2/p-tau1 subjects clinically progress at a rate similar to that of MCI subjects who are biomarker negative. This reduced rate of progression of our SNAP MCI Ab2/ptau1 population may be explained by the fact that CSF p-tau reflects neurofibrillary tangles pathology rather than neuronal degeneration [7] . Importantly, the clinical stability of MCI Ab2/p-tau1 participants supports the synergism between Ab and p-tau pathologies as a key element triggering AD dementia [1, 10] . The reduced rate of clinical progression web 4C=FPO web 4C=FPO Fig. 2 . The amnestic MCI Ab1/p-tau1 individuals present the lowest baseline scores and the highest rate of decline in most neuropsychological functions. The values are presented in z-scores anchored in normative data of a cognitively normal population. In the box and whisker plots, the lower and upper boundaries show the 25th and 75th percentiles, respectively, whereas the horizontal line shows the median. The dots represent mild cognitive impairment (MCI) individuals less than the fifth or higher than the 95th percentile. Bonferroni-corrected P values for multiple comparisons indicate the values assessed with analyses of covariance adjusted for age, gender, years of education, APOE ε4 status, and baseline neuropsychological test score for longitudinal analysis. Post hoc multiple comparison analysis provided significant differences between biomarker groups for each neuropsychological test at *P , .05 and **P , .001. (A) At baseline, the Ab1/p-tau1 group presented the lowest baseline scores in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), logical memory immediate recall (LMI), and 30-minute delayed recall (LM30). The Ab1/p-tau1 group showed worse performance in the Trail Making Test part B (TMT-B) than the Ab2/p-tau2 and Ab2/p-tau1 groups. (B) The Ab1/p-tau1 group presented the highest longitudinal impairment in all neuropsychological tests except TMT-A and MMSE. Ab1/p-tau1 group showed higher decline in MMSE than Ab2/p-tau2 and Ab2/p-tau1 groups. Notably, Ab2/p-tau2, Ab1/p-tau2, and Ab2/p-tau1 groups did not differ from each other in any baseline or longitudinal cognitive performance. Abbreviations: Ab, amyloid-b; p-tau, phosphorylated tau. of our SNAP MCI Ab2/p-tau1 group as compared to that observed in previous studies may be due to the presence of a significant proportion of MCI individuals who are in the early clinical stages of MCI in the ADNI-GO/2 cohort [11, 12] . This is consistent with studies on cognitively normal individuals showing that SNAP progresses at a rate similar to that of biomarker negative subjects [3, 13] . Furthermore, it is possible that the cognitive decline observed in SNAP MCI in previous studies, defined by less-specific biomarkers for AD such as brain hypometabolism or atrophy, was driven by other pathophysiological processes such as TDP-4, alpha-synuclein inclusions, and hippocampal sclerosis [14, 15] . Together, these results support that SNAP MCI individuals characterized by the presence of p-tau pathology, different from those with SNAP MCI defined by neuronal degeneration biomarkers, clinically progress at rates comparable to those seen in MCI biomarker negative individuals. 18 F]florbetapir SUVR and CSF p-tau in temporal and inferior parietal cortices predicts progression to dementia. T-statistical parametric map, after correcting for multiple comparisons (random field theory at P , .001), overlaid in a structural magnetic resonance scan revealed that lateral and basal temporal and inferior parietal cortices were the brain regions where the synergism between [ 18 F]florbetapir standardized uptake value ratio (SUVR) and cerebrospinal fluid (CSF) phosphorylated tau (p-tau) status was associated with an increased likelihood of progression to Alzheimer disease (AD) dementia over 2 years.
This study has some methodological limitations. Biomarkers provide naturally continuous measurements; therefore, thresholds are invariably subject to conceptual and analytical idiosyncrasies and may change depending on the method of analysis used. However, the use of regression models with continuous biomarker values helped prevent our results from being driven by the use of more liberal or more conservative biomarker threshold. Additionally, we assessed the synergy between Ab and p-tau across all brain voxels. To the best of our knowledge, this is the first study conducting a voxel-based logistic regression analysis to evaluate progression to dementia using Ab PET imaging. Importantly, our results showing the synergism between amyloid-b and p-tau leading to downstream clinical progression do not exclude the possibility that these two proteinopathies might arise sequentially (e.g., amyloid-b triggering the spreading of tau over the neocortex early on in the pathophysiological progression [14] ). Certainly, cell cultures and in vivo studies with long-term imaging of amyloidb and p-tau in animal models and in humans could better investigate causal and temporal relationships between these proteins. It is also important to mention that the observations reported here do not to prove a biological synergy between Ab and p-tau proteins. Our overall progression rate to dementia was 19% over 2 years. Previous studies conducted in memory clinic cohorts have reported progression rate in MCI of up to 59% over 2 years [31] . This might be explained by the fact that the ADNI-GO/2 inclusion criteria include MCI individuals in a less-advanced disease stage as compared to these cohorts [32] . In fact, our findings are similar to a recent study involving MCI ADNI-GO/2 participants that reported an overall progression rate of 15% over 1.6 years [33] . Finally, regarding the population included in this analysis, it is important to emphasize that it represents a select group of amnestic MCI persons motivated to participate in a dementia study. As such, for reasons related to the study inclusion criteria and self-selection bias [34] , these individuals may not represent the general MCI population. Therefore, it would be highly desirable to replicate our findings on a population-based cohort.
From a clinical perspective, if replicated, such a synergism has important implications in understanding the dynamics of progression to dementia. For example, the clinical stability of nondemented persons with biomarker abnormalities described in numerous cohorts [35, 36] could be explained by the absence of convergence of the Ab and p-tau pathways, postulated here to be crucial for imminent clinical progression in amnestic MCI. In addition, the combination of abnormal amyloid-PET and CSF p-tau biomarkers may represent a valuable strategy for the enrichment of amnestic MCI populations with individuals having a high probability of developing AD dementia in therapeutic clinical trials targeting Ab or tau aggregates.
From a therapeutic perspective, one can derive important predictions from the existence of a synergistic interaction between Ab and p-tau in AD. For example, one can predict that therapeutic interventions targeting either Ab or p-tau pathology might similarly mitigate AD progression. Furthermore, the same synergistic model implies better effectiveness of a combined therapeutic approach targeting both, Ab and p-tau, pathological pathways. However, it is important to mention that the synergism between pathological pathways might not always translate into synergistic effects of multiple treatments. Importantly, this model should be supported by further studies combining long-term sequential biomarker and clinical observations.
In conclusion, our results support the synergism between Ab and tau pathologies as a driving force behind the clinical progression to AD dementia.
RESEARCH IN CONTEXT
1. Systematic review: Cross-sectional and longitudinal studies conducted in animal models and in cognitively healthy individuals provide evidences suggesting that the interaction between amyloid-b (Ab) and phosphorylated tau (p-tau) imposes neurodegeneration. However, the link between Ab and p-tau as a determinant to the clinical progression to dementia remains unclear.
2. Interpretation: We tested the hypothesis that the synergistic interaction between Ab and p-tau is a driving force behind the progression from amnestic mild cognitive impairment (MCI) to Alzheimer disease dementia. Our results support a framework in which Ab and p-tau synergistic effect best predicts cognitive decline and dementia, as compared to the sum of their individual effects.
3. Future directions: Future clinical trials focusing on MCI should consider enrich study populations with individuals presenting the coexistence of Ab and p-tau abnormalities, to include participants with a higher probability of developing dementia in short time frames.
